Pharmacologic treatment of hypertension in the Department of Veterans Affairs during 1995 and 1996

David Siegel, Julio Lopez, Joy Meier

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Patterns of antihypertensive drug use, the cost of this care and potential savings with changes of treatment patterns, were studied for all hypertensives treated at US Veterans Affairs (VA) medical facilities for fiscal years 1995 and 1996. Data was aggregated by individual medication as well as by antihypertensive drug class. Cost estimates were based on median cost and number of units for each dosage form of each medication dispensed at all facilities. Potential savings were estimated by substituting β-blockers or diuretics for calcium antagonists. In a subset of patients the prevalence of hypertension, and among hypertensives the prevalence of coronary artery disease, congestive heart failure, and diabetes mellitus, was determined. For these patients, patterns of treatment by antihypertensive drug class was examined. For all VA facilities, of the 10 most frequently prescribed antihypertensives in 1995, four were calcium antagonists, two angiotensin converting enzyme (ACE) inhibitors, two β-blockers, and two diuretics. In 1996, this was changed by the addition of an ACE inhibitor and the subtraction of a diuretic combination. Calcium antagonists accounted for 37% of treatment days in 1995 and 35% in 1996, ACE inhibitor use went from 34% to 36%, β-blockers from 17% to 18%, and diuretic use remained at 12%. In 1996, approximately 86.6 million dollars were spent on calcium antagonists, 51.8 million on ACE inhibitors, 7.9 million on β-blockers, and 3.6 million on diuretics. The estimated annual cost savings for each 1% conversion of calcium antagonists to β-blockers would be $713,000 and to diuretics $758,000. In a subset of 7526 hypertensive patients with known comorbid conditions, calcium antagonists and ACE inhibitors were also the most commonly used drug classes for all categories of patients, including those without coronary artery disease, congestive heart failure, and diabetes mellitus. Calcium antagonists and ACE inhibitors were the most commonly dispensed antihypertensives at VA facilities for both 1995 and 1996, with a small decrease in calcium antagonist use from 1995 to 1996. The cost implications of these practice patterns as compared with the primary use of diuretics and β-blockers are enormous.

Original languageEnglish (US)
Pages (from-to)1271-1278
Number of pages8
JournalAmerican Journal of Hypertension
Volume11
Issue number11 I
DOIs
StatePublished - Nov 1998

Fingerprint

Veterans
Diuretics
Angiotensin-Converting Enzyme Inhibitors
Hypertension
Calcium
Antihypertensive Agents
Therapeutics
Costs and Cost Analysis
Coronary Artery Disease
Diabetes Mellitus
Heart Failure
United States Department of Veterans Affairs
Drug Costs
Cost Savings
Dosage Forms
Pharmaceutical Preparations

Keywords

  • Adrenergic β-antagonists
  • Angiotensin-converting enzyme inhibitors
  • Calcium channel blockers
  • Cost control
  • Diuretics
  • Health care costs
  • Hypertension

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Pharmacologic treatment of hypertension in the Department of Veterans Affairs during 1995 and 1996. / Siegel, David; Lopez, Julio; Meier, Joy.

In: American Journal of Hypertension, Vol. 11, No. 11 I, 11.1998, p. 1271-1278.

Research output: Contribution to journalArticle

@article{2e8e5586812a421bb83fc63cf98560ef,
title = "Pharmacologic treatment of hypertension in the Department of Veterans Affairs during 1995 and 1996",
abstract = "Patterns of antihypertensive drug use, the cost of this care and potential savings with changes of treatment patterns, were studied for all hypertensives treated at US Veterans Affairs (VA) medical facilities for fiscal years 1995 and 1996. Data was aggregated by individual medication as well as by antihypertensive drug class. Cost estimates were based on median cost and number of units for each dosage form of each medication dispensed at all facilities. Potential savings were estimated by substituting β-blockers or diuretics for calcium antagonists. In a subset of patients the prevalence of hypertension, and among hypertensives the prevalence of coronary artery disease, congestive heart failure, and diabetes mellitus, was determined. For these patients, patterns of treatment by antihypertensive drug class was examined. For all VA facilities, of the 10 most frequently prescribed antihypertensives in 1995, four were calcium antagonists, two angiotensin converting enzyme (ACE) inhibitors, two β-blockers, and two diuretics. In 1996, this was changed by the addition of an ACE inhibitor and the subtraction of a diuretic combination. Calcium antagonists accounted for 37{\%} of treatment days in 1995 and 35{\%} in 1996, ACE inhibitor use went from 34{\%} to 36{\%}, β-blockers from 17{\%} to 18{\%}, and diuretic use remained at 12{\%}. In 1996, approximately 86.6 million dollars were spent on calcium antagonists, 51.8 million on ACE inhibitors, 7.9 million on β-blockers, and 3.6 million on diuretics. The estimated annual cost savings for each 1{\%} conversion of calcium antagonists to β-blockers would be $713,000 and to diuretics $758,000. In a subset of 7526 hypertensive patients with known comorbid conditions, calcium antagonists and ACE inhibitors were also the most commonly used drug classes for all categories of patients, including those without coronary artery disease, congestive heart failure, and diabetes mellitus. Calcium antagonists and ACE inhibitors were the most commonly dispensed antihypertensives at VA facilities for both 1995 and 1996, with a small decrease in calcium antagonist use from 1995 to 1996. The cost implications of these practice patterns as compared with the primary use of diuretics and β-blockers are enormous.",
keywords = "Adrenergic β-antagonists, Angiotensin-converting enzyme inhibitors, Calcium channel blockers, Cost control, Diuretics, Health care costs, Hypertension",
author = "David Siegel and Julio Lopez and Joy Meier",
year = "1998",
month = "11",
doi = "10.1016/S0895-7061(98)00158-7",
language = "English (US)",
volume = "11",
pages = "1271--1278",
journal = "American Journal of Hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "11 I",

}

TY - JOUR

T1 - Pharmacologic treatment of hypertension in the Department of Veterans Affairs during 1995 and 1996

AU - Siegel, David

AU - Lopez, Julio

AU - Meier, Joy

PY - 1998/11

Y1 - 1998/11

N2 - Patterns of antihypertensive drug use, the cost of this care and potential savings with changes of treatment patterns, were studied for all hypertensives treated at US Veterans Affairs (VA) medical facilities for fiscal years 1995 and 1996. Data was aggregated by individual medication as well as by antihypertensive drug class. Cost estimates were based on median cost and number of units for each dosage form of each medication dispensed at all facilities. Potential savings were estimated by substituting β-blockers or diuretics for calcium antagonists. In a subset of patients the prevalence of hypertension, and among hypertensives the prevalence of coronary artery disease, congestive heart failure, and diabetes mellitus, was determined. For these patients, patterns of treatment by antihypertensive drug class was examined. For all VA facilities, of the 10 most frequently prescribed antihypertensives in 1995, four were calcium antagonists, two angiotensin converting enzyme (ACE) inhibitors, two β-blockers, and two diuretics. In 1996, this was changed by the addition of an ACE inhibitor and the subtraction of a diuretic combination. Calcium antagonists accounted for 37% of treatment days in 1995 and 35% in 1996, ACE inhibitor use went from 34% to 36%, β-blockers from 17% to 18%, and diuretic use remained at 12%. In 1996, approximately 86.6 million dollars were spent on calcium antagonists, 51.8 million on ACE inhibitors, 7.9 million on β-blockers, and 3.6 million on diuretics. The estimated annual cost savings for each 1% conversion of calcium antagonists to β-blockers would be $713,000 and to diuretics $758,000. In a subset of 7526 hypertensive patients with known comorbid conditions, calcium antagonists and ACE inhibitors were also the most commonly used drug classes for all categories of patients, including those without coronary artery disease, congestive heart failure, and diabetes mellitus. Calcium antagonists and ACE inhibitors were the most commonly dispensed antihypertensives at VA facilities for both 1995 and 1996, with a small decrease in calcium antagonist use from 1995 to 1996. The cost implications of these practice patterns as compared with the primary use of diuretics and β-blockers are enormous.

AB - Patterns of antihypertensive drug use, the cost of this care and potential savings with changes of treatment patterns, were studied for all hypertensives treated at US Veterans Affairs (VA) medical facilities for fiscal years 1995 and 1996. Data was aggregated by individual medication as well as by antihypertensive drug class. Cost estimates were based on median cost and number of units for each dosage form of each medication dispensed at all facilities. Potential savings were estimated by substituting β-blockers or diuretics for calcium antagonists. In a subset of patients the prevalence of hypertension, and among hypertensives the prevalence of coronary artery disease, congestive heart failure, and diabetes mellitus, was determined. For these patients, patterns of treatment by antihypertensive drug class was examined. For all VA facilities, of the 10 most frequently prescribed antihypertensives in 1995, four were calcium antagonists, two angiotensin converting enzyme (ACE) inhibitors, two β-blockers, and two diuretics. In 1996, this was changed by the addition of an ACE inhibitor and the subtraction of a diuretic combination. Calcium antagonists accounted for 37% of treatment days in 1995 and 35% in 1996, ACE inhibitor use went from 34% to 36%, β-blockers from 17% to 18%, and diuretic use remained at 12%. In 1996, approximately 86.6 million dollars were spent on calcium antagonists, 51.8 million on ACE inhibitors, 7.9 million on β-blockers, and 3.6 million on diuretics. The estimated annual cost savings for each 1% conversion of calcium antagonists to β-blockers would be $713,000 and to diuretics $758,000. In a subset of 7526 hypertensive patients with known comorbid conditions, calcium antagonists and ACE inhibitors were also the most commonly used drug classes for all categories of patients, including those without coronary artery disease, congestive heart failure, and diabetes mellitus. Calcium antagonists and ACE inhibitors were the most commonly dispensed antihypertensives at VA facilities for both 1995 and 1996, with a small decrease in calcium antagonist use from 1995 to 1996. The cost implications of these practice patterns as compared with the primary use of diuretics and β-blockers are enormous.

KW - Adrenergic β-antagonists

KW - Angiotensin-converting enzyme inhibitors

KW - Calcium channel blockers

KW - Cost control

KW - Diuretics

KW - Health care costs

KW - Hypertension

UR - http://www.scopus.com/inward/record.url?scp=0031770532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031770532&partnerID=8YFLogxK

U2 - 10.1016/S0895-7061(98)00158-7

DO - 10.1016/S0895-7061(98)00158-7

M3 - Article

C2 - 9832168

AN - SCOPUS:0031770532

VL - 11

SP - 1271

EP - 1278

JO - American Journal of Hypertension

JF - American Journal of Hypertension

SN - 0895-7061

IS - 11 I

ER -